NEUROMICS

Gefitinib Data Sheet

Catalog Number:	MC11090	**Product Type:**	Small Molecule
Bio-Activity:	EGFR-Kinase inhibitor	**CAS #:**	184475-35-2
Research Categories:	Angiogenesis, cell death, cancer	**Chemical Name:**	N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
Solubility:	Soluble in DMSO (up to 40 mg/ml) or in Ethanol (up to 4 mg/ml).	**Molecular Formula:**	C22H24ClFN4O3
Purity:	> 98%	**Molecular Weight:**	446.91
Format:	Powder	**Ship Temp:**	Ambient
Storage:	Room Temperature		

Application Notes

Description/Data:
Potent and selective EGFR kinase inhibitor (IC50 = 23-79 nM) [1]. Inhibits EGFR autophosphorylation and inhibits tumor growth in vivo [2]. Enhances efficacy of cytotoxic agents [3]. Inhibits growth factor production and angiogenesis [4]. Clinically useful anticancer agent.

References:

1) Baselga et al. (2000), ZD1839 ('Iressa') as an anticancer agent; Drugs, 60 33

2) McKillop et al. (2005), Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor; Mol. Cancer Ther., 4 641

3) Sirotnak et al. (2000), Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase; Clin. Cancer Res., 6 4885

4) Ciaradiello et al. (2001), Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor; Clin. Cancer Res., 7 1459

FOR RESEARCH USE ONLY

Neuromics Antibodies • 5325 West 74th Street, Suite 8 • Edina, MN 55439
phone 866-350-1500 • fax 612-677-3976 • e-mail: pshuster@neuromics.com